Fosaprepitant as combination therapy to prevent chemotherapy-induced vomiting in children: a meta-analysis by Yanshuo Shi, Yanshuo Shi, Yuanyuan Yue, Yuanyuan Yue, Yue Zhang, Guoxun Pang

“…ObjectiveTo systematically evaluate the clinical efficacy and safety of fosaprepitant combined with 5-hydroxytryptamine 3 receptor antagonists (5-HT3RA) (with or without dexamethasone) on the chemotherapy-induced vomiting in pediatric cancer patients.MethodsPubMed, Embase, Cochrane Library, China Journal full-text database (CNKI), Wanfang data knowledge service platform (Wanfang) and VIP Chinese sci-tech Journal full-text database (VIP) were searched by computer (retrieval time from database establishment to Apr. 2024), randomized controlled trials (RCTs) and cohort studies about fosaprepitant and 5-HT3RA with or without dexamethasone (observation group) versus 5-HT3RA, with or without dexamethasone, as the control group for chemotherapy-induced vomiting were collected, after data extraction and quality evaluation, meta-analysis was carried out by Rev Man 5.3 software.ResultsA total of 731 patients were included in 7 trials. …”
Get full text